Osang Healthcare Achieves 140 Billion KRW in Diagnostic Kit Sales and 110 Billion KRW Operating Profit in Q2

[Asia Economy Reporter Oh Ju-yeon] Osang Healthcare, a subsidiary of Osang Jaiel specializing in medical diagnostic devices, announced on the 22nd that its sales for the second quarter of this year amounted to 140 billion KRW, with an operating profit of 110 billion KRW.

An Osang Healthcare official stated, "Osang Healthcare, which was the first in Korea to obtain European certification and the U.S. Food and Drug Administration (FDA) emergency use authorization, has exported diagnostic kits to several overseas countries without any quality issues. The excellence of our products has become widely recognized, resulting in steady orders," adding, "We expect significant sales growth in the second half of the year through active order acquisition activities."

The company has expanded its production system and capacity to produce 15 million tests per week to ensure no issues arise despite large overseas orders. Some inventory has also been stockpiled for rapid response.

A company representative said, "Osang Healthcare is building the largest antigen-antibody rapid diagnostic kit production facility in Korea, in addition to the existing PCR molecular diagnostic method, to become the largest specialized diagnostic kit company in the country."

Meanwhile, Osang Healthcare is a specialized medical device company for diagnosing various adult diseases and viral infections and is recognized as a World Class 300 Hidden Champion small and medium enterprise selected by the government.

This content was produced with the assistance of AI translation services.